JAK2 and myeloproliferative neoplasm: On the contrary, targeting ERK2 docking D-domain lead to a reduced proliferation of human and murine MPN cells, proving ERK-domain specific role in MPN pathogenesis and supporting development of agents targeting JAK2 and MAPK dependent MPN [133].